Table 3.
Main characteristics and treatment modalities of patients with endometrial cancer undergoing FSS.
| Patient Characteristics | |
|---|---|
| Total n of patients | 1229 |
| Age (y), median (range) | 32.6 (31–36.1) |
| Tumor characteristics | n of patients (%) |
| FIGO stage | |
| IA | 1020 (83.0) |
| IB | 6 (0.5) |
| IB-IIA | 15 (1.2) |
| I nos | 188 (15.3) |
| Histological subtype | |
| endometrioid | 1110 (90.3) |
| adenosquamous | 10 (0.8) |
| mucinous | 1 (0.1) |
| mixed | 8 (0.7) |
| adenocarcinoma nos | 35 (2.8) |
| na | 65 (5.3) |
| Grade | |
| 1 | 1136 (92.4) |
| 2 | 86 (7.0) |
| 3 | 4 (0.3) |
| na | 3 (0.2) |
| Treatment modalities * | n of patients (%) |
| Type of FSS | |
| D&C | 245 (19.9) |
| HR | 155 (12.6) |
| HR + D&C | 57 (4.6) |
| NR | 772 (62.8) |
| Hormonal therapy | |
| MPA | 458 (37.3) |
| MA | 337 (27.4) |
| LNG-IUD | 91 (7.4) |
| MPA + MA | 7 (0.6) |
| MPA/MA + LNG-IUD | 26 (2.1) |
| MPA/MA + metformin | 57 (4.6) |
| MPA/MA nos | 198 (16.1) |
| Progestin nos | 51 (4.1) |
| Other ^ | 4 (0.3) |
FSS—fertility-sparing surgery; HR—hysteroscopic resection; D&C—dilatation and curettage; MA—megestrol acetate; MPA—medroxy-progesterone acetate; LNG-IUD—levonorgestrel intrauterine device; nos—not otherwise specified; na—not available; NR—not reported; * Limited to publications with available data; ^ norethisterone acetate (n = 2) and hydroxyprogesterone caproate (n = 2).